OVOCA BIO PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.01 EUR | -.--% |
|
-.--% | -.--% |
| 07-15 | Jet2 chair buys; Ovoca Bio's old CEO sells to new | AN |
| 07-15 | Ovoca Bio CEO to Resign in August; Successor Named | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Ovoca Bio Plc is a biopharmaceutical company specialized in the development and manufacturing of peptides for the treatment of female sexual dysfunction.
At the end of 2022, the Group had a product in phase III clinical development (Orenetide).
Calendar
25/09/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 890K | |
| +20.63% | 127B | |
| +24.89% | 27.67B | |
| -20.17% | 20.33B | |
| -16.68% | 16.79B | |
| -18.07% | 15.63B | |
| -47.70% | 14.65B | |
| +11.92% | 14.84B | |
| +58.32% | 14.43B | |
| +149.98% | 12.49B |
- Stock Market
- Equities
- OVXA Stock
- OVXA Stock
- News Ovoca Bio plc
- Ovoca Bio Shares Plunge 80% as Orenetide Fails Mid-stage Trial
